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ABI - Applied Biosystems 
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BAP - Blood agar plate 
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PCR – Polymerase Chain Reaction 
ProK-  Proteinase K 
RFU – Relative fluorescence units  




SDS- Sodium dodecyl sulfate  
TE – Tris + EDTA  
TNE – Tris+ NaCl (sodium chloride)+ EDTA 







 Chapter I. Introduction 
The increasing incidence of methicillin resistance in Staphylococcus infections  
has created a therapeutic challenge that necessitates a better understanding of antibiotic 
resistance (Arias & Murray, 2009).  Methicillin-resistant S. aureus (MRSA) tends also to 
be resistant to many other antibiotics currently used in the treatment of infections. By 
understanding how methicillin resistance is inherited and maintained by S. aureus, the 
spread of MRSA could potentially be prevented by appropriate therapeutic measures. 
  S. aureus is a gram-positive spherical bacterium, commonly found in the nares 
and on the skin of 25 to 30% of the U.S. population (CDC, 2011). S. aureus causes both 
local and systemic diseases; including soft tissue infections, scalded skin syndrome, toxic 
shock syndrome, osteomyelitis, and pneumonia (Goetghebeur, Landry, Han, & Vincente, 
2006). Staphylococcal infections can be particularly harmful to immunocompromised 
individuals.  
Recent research has shown that antimicrobial therapy may be a major factor 
associated with the development of methicillin resistance. Treatment with multiple drugs 
may result in multiple resistances, thereby increasing the difficulty for successful 
treatment (Lu, et al, 2005).  Understanding these relationships is essential in the detection 
and treatment of MRSA. 




gene has been identified in MRSA isolates and is absent in methicillin-susceptible S. 
aureus (MSSA) (Petersson, Kamme, & Miorner, 1999). The mecA gene is located on a 
21-kb to 67-kb mobile element known as the staphylococcal cassette chromosome mec 
(SCCmec). The mobility of this element contributes to its reputation as the major 
component of gene transference (Wielders, Fluit, Brisse, Verhoef, & Schmitz, 2002). The  
mecA gene product is responsible for the general ineffectiveness of ß-lactam antibiotics, 
including methicillin.  mecA expression results in the production of penicillin-binding 
protein 2a (PBP 2a). Beta-lactam antibiotics such as methicillin inhibit bacterial cell wall 
synthesis by binding to normally occurring penicillin-binding proteins (PBP). 
Insensitivity to methicillin is due to the low binding affinity of mecA-encoded PBP 2a, a 
transglycosylase and transpeptidase molecule (Walsh, 2003). Therefore, the resistance of 
S. aureus to methicillin and other ß -lactam antibiotics can be determined by the 
expression of the mecA gene or the presence of the PBP 2a protein. However, it must be 
noted that methicillin resistance cannot be solely attributed to mecA expression as other 
factors may be involved. Intrinsically produced modified penicillin-binding proteins 
(MOD-PBPs) and overproduction of β-lactamases are also considered mechanisms of 
resistance (Tomasz et al., 1989, McDougal & Thornsberry, 1986).  
 The origin of mecA in S. aureus has not been elucidated, however; many 
hypotheses support the idea of interspecies transfer. Epidemiology suggests that 
acquisition of mecA is accomplished through horizontal gene transfer. Genetic material 
can be transferred between bacteria by three known mechanisms: transduction, 
conjugation, and transformation. Transduction is the transfer of bacterial genetic material 




contact and transfer of genetic material incorporated into a plasmid via a pilus. 
Transformation occurs when a bacterial cell takes up foreign DNA from the environment 
and incorporates it into its genome for subsequent expression.  This study focuses on 
transformation as a potential mechanism for mecA transference. The abundance of DNA 
in the environment resulting from cellular lysis provides a rich pool of genetic material 
available to bacteria. The aim of this research is to document the transference of a 
functional mecA gene from MRSA genomic DNA to methicillin-sensitive S. aureus 





 Chapter II. Review of Literature 
2.1.  Staphylococcus aureus Infections 
2.1.1. Pathogenicity of MRSA  
 Staphylococcus species are ubiquitous in nature.  The CDC estimates that 25 to 
30 percent of both healthy individuals and immunocompromised patients harbor this 
microorganism (CDC, 2011). Diseases caused by S. aureus range from localized skin 
rashes to life-threatening systemic diseases. Pathogenicity of S. aureus is associated with 
a number of virulence factors. Protein A is an example of a surface factor that allows the 
bacterium to evade phagocytosis by binding to IgM. Other virulence factors contribute to 
disease by interfering with the body’s immune response.  Degradative enzymes such as 
hyaluronidase, nuclease, and protease are examples of virulence factors that facilitate the 
spread of the bacterium. S. aureus can attack the immune system directly by secretion of 
hemolysins and leukocidins; toxins that are capable of disabling and killing phagocytes. 
Pyrogenic toxins act as superantigens, causing a harmful release of cytokines. 
Staphylococcal enterotoxins can cause vomiting, diarrhea, and related symptoms of food 
poisoning. Toxic Shock Syndrome (TSS) is commonly associated with S. aureus and is a 
result of the secretion of the Toxic Shock Syndrome Toxin (TSST-1).  Symptoms 




hypotension, and potentially septic shock. Additionally, staphylococcal scalded skin 
syndrome (SSSS) causes severe blistering of the skin due to exfoliative toxins produced 
by the microorganism (Wing & Kulkarni, 2010). The relationship between these 
virulence factors and MRSA-related diseases has not been clearly established.  The 
cumulative effects of pathogenicity and methicillin resistance are self-evident.   
2.1.2. Morbidity/Mortality  
 S. aureus may colonize the nasal passages and/or skin of asymptomatic carriers. 
MRSA infections can result in sepsis, cellulitis, endocarditis, pneumonia, and/or TSS. 
The cumulative effects of these infections are highly dependent on the overall health of 
the individual. A weakened immune system coupled with a serious staphylococcal 
infection may be lethal as demonstrated by the high mortality rates associated with 
MRSA-related pneumonia and sepsis (Dugdale & Vyas, 2009). 
 
2.2. Antibiotic Treatments 
2.2.1. Methicillin and Other Structurally-related Compounds 
(Oxacillin) 
  Resistance to penicillin resulted in the use of methicillin as an alternative 
treatment for S. aureus infections (Enright et al., 2002). A few years after the 
introduction of methicillin, methicillin resistance was detected in the United Kingdom 
(1961). As a beta-lactam antibiotic, methicillin is structurally related to penicillin and 




proteins (PBPs) inhibits cell wall synthesis. PBP acts as a catalyst in the cross-linking of 
peptides in the peptidoglycan component of the staphylococcal cell wall. Interference 
with bacterial cell wall synthesis is disruptive to the normal maintenance and growth of 
bacteria, resulting in cellular death. Methicillin is no longer commercially produced in the 
United States and has been replaced by oxacillin in clinical use (CDC, 2011). Although 
oxacillin is used clinically to test for resistance, resistant strains are still referred to as 
methicillin-resistant S. aureus due to its historical significance.  
2.2.2. Multiple Resistance 
Treatment of MRSA infections becomes even more problematic when resistance 
is not limited to methicillin, but also to other commonly used antibiotics. Clinical 
research has demonstrated that antibiotic treatment may become a major factor in the 
colonization of MRSA. Treatment of MRSA infections with multiple antibiotics has 
contributed to the already difficult process of eliminating the bacteria (Lu, et al., 2005). 
S. aureus that are resistant to methicillin are usually resistant to other beta-lactam 
antibiotics, including penicillin G and cephalosporins (Katayama, Ito, & Hiramatsu, 
2000). The factors contributing to resistance in MRSA are similar to penicillin G 
resistance in strains of S. aureus (Chambers, 2001). MRSA can also exhibit resistance to 
aminoglycosides and tetracycline (Parker & Hewitt, 1970). MRSA infections are 
generally treated with a combination of antibiotics including:  clindamycin, daptomycin, 
doxycycline, linezolid, minocycline, tetractycline, trimethoprim-sulfamethoxazole, 






Resistance to methicillin has been reported in hospitals as well as in the 
community. MRSA infections are currently classified as either community-acquired (CA-
MRSA) or hospital-acquired MRSA (HA-MRSA). It has been postulated that MRSA 
originated in the hospital environment due to the indiscriminate use of antibiotics 
(Chambers, 2001). In contrast, MRSA infections are considered to be community-
acquired (CA-MRSA) only if the patient meets certain criteria such as no recent surgery, 
no implanted medical devices, or no recent antibiotic therapy.  In addition, the patient 
should not have taken residence in a long-term care facility nor have been recently 
hospitalized with a history of HA-MRSA (Demling & Waterhouse, 2007). Several 
studies have attempted to identify genetic differences in order to characterize and classify 
CA-MRSA and HA-MRSA.   
2.3.2. Difference between CA-MRSA and HA-MRSA 
Strains of MRSA originating from hospitals (HA- MRSA) are generally resistant 
to multiple antibiotics in contrast to their community-acquired counterpart (CA-MRSA) 
(Chambers, 2001). This finding can be explained by the lower antibiotic selective 
pressures in the community as compared to the hospital environment. However, this 
epidemiology of S. aureus has changed substantially in recent years. The dissemination 
of HA- MRSA into the community has made it difficult to distinguish between HA- and 
CA-MRSA. The origin of CA-MRSA has been speculated to be the consequence of 




Molecular typing of CA-MRSA and HA-MRSA has demonstrated differences in their 
antibiotic susceptibilities. HA-MRSA commonly contain resistance genes to other 
antibiotics in addition to the methicillin resistance determinant which are generally absent 
in CA-MRSA. In 2007, Boyle-Vavra and Daum examined the correlation between 
virulence and MRSA. They identified a possible link between CA-MRSA and Panton-
Valentine Leukocidin (PVL) toxin. 
2.4.  Methicillin Resistance 
2.4.1. Resistance Mechanisms 
S. aureus is able to circumvent the lethal effects of methicillin by a combination 
of multiple mechanisms of resistance. One of those mechanisms is the production of 
modified penicillin-binding proteins (MOD-PBPs). Methicillin acts by binding to 
intrinsically produced PBPs thereby inhibiting cell wall synthesis. MOD-PBPs have a 
substantially reduced affinity for methicillin as compared to normal PBPs allowing near 
normal levels of cell wall synthesis (Tomasz et al., 1989). In addition to MOD-PBPs, a 
second mechanism of resistance is the overproduction of beta-lactamases that can 
inactivate methicillin. The large amount of beta-lactamase produced can lead to the rapid 
hydrolysis of penicillin and partial hydrolysis of penicillinase-resistant antibiotics such as 
oxacillin, cephalosporins, and methicillin (McDougal & Thornsberry, 1986) thereby 
conferring resistance. These mechanisms have been more commonly associated with 
borderline-resistant S. aureus. Classical resistance is primarily attributed to the 
methicillin resistance determinant (mecA) which is detectable in MRSA isolates while 




binding protein 2a (PBP 2a) (Archer, et al., 1994) and is located on a novel genetic 
mobile element, Staphylococcal Cassette Chromosome mec (SCCmec).  
2.4.2. Defining Resistance 
Expression of methicillin resistance (mecA) in MRSA is characteristically 
heterogeneous. This heterogeneity is ill-defined and results in difficulties detecting 
methicillin resistance. A culture of MRSA may contain two subpopulations; one 
susceptible and the other resistant to methicillin. Although all of the cells in that culture 
may be genetic clones containing mecA, not all of the cells may express the gene 
therefore appear to be sensitive to methicillin. The Clinical Laboratory of Standards 
Institute (CLSI) developed standard protocols for the identification of MRSA and MSSA. 
They use several methods to phenotypically distinguish MRSA from MSSA. CLSI 
established the interpretive criteria for MIC oxacillin susceptibility as less than 2 μg/ml 
for MSSA and greater than 4 μg/ml for MRSA (Murray et al., 2009). The polymerase 
chain reaction (PCR) is the accepted standard used to confirm the presence of the mecA 
gene.   
2.4.3. SCCmec Types 
Molecular typing of the staphylococcal cassette chromosome mec (SCCmec) 
isolated from MRSA has revealed differences in size and sequence of the genetic 
element. At least five different types of SCCmec (I - V) have been identified thus far 
(Figure 1). The different SCCmec types range in size between 21- to 67-kb and differ in 
their combinations of complexes. The mobile element contains two main complexes: a 




ccr and mec complexes, SCCmec is comprised of a J-region (Junkyard region), which can 
also be used to distinguish among various SCCmec types (Hanssen & Sollid, 2006). The 
mec complex contains the mecA gene and is categorized into different classes with 
different combinations of mecI and mecR (Figure 2). Expression of the mecA gene is 
regulated by the mecR1-mecI, a two gene operon that is located upstream from mecA. The 
mecR1 gene encodes a signal sensor and mecI encodes a transducer (Ito et al., 1999 & Ito 
et.al, 2004). There are five different known allotypes of ccr. The ccr complex codes for 
site-specific recombinases that effectively, excise and integrate SCCmec into the 
chromosome (Katayama et al., 2000). Therefore, the mobile element in which mecA is 
located can be specifically integrated into the  chromosome of S. aureus and potentially 
lead to the expression of methicillin resistance. The mobility of this element gives rise to 
the possibility of transference of methicillin resistance between bacterial cells. SCCmec 
types I, IV, and V do not contain any antibiotic resistance genes other than the methicillin 
resistance determinant. They are generally associated with CA-MRSA (Hanssen & 


































































































































* Illus. in Chambers, 2001. The mec gene complexes present in different SCCmec 
  mobile elements. 
 
 




2.4.4. Stability of mecA 
The SCCmec element harbors the mecA gene complex which codes for penicillin-
binding protein 2a, a 76 kDa protein (Tomasz, et al., 1989). As such, PBP 2a production 
is responsible for methicillin resistance. PBP 2a has a lower binding affinity to 
methicillin which enables cell wall assembly and subsequently confers resistance. 
Transfer of this gene may provide a selective advantage for S. aureus under antibiotic 
pressure. However, the acquisition and maintenance of the mecA complex requires 
increased energy demands on the bacteria, not found in non-mecA cells and apparently 
comes at a fitness cost to the bacterial cell. Cells containing the mecA complex grow at a 
slower rate in order to maintain relatively large amounts of SCCmec (Ender, et al., 2004). 
A longevity study conducted by Griethuysen et al (2005) demonstrated that MRSA 
strains can lose the mecA gene after years of storage at -80C. Chambers (2001) stated 
“only a handful of ancestral strains account for all clinical isolates worldwide.” The 
acquisition of mecA may therefore only prove to be a transient advantage under selective 
conditions.  
2.5. Transference 
2.5.1. Mechanisms of Genetic Exchange 
Although mecA is widely distributed among S. aureus, its origin is still obscure. 
Epidemiological studies have suggested that methicillin resistance in S. aureus is 
acquired via horizontal gene transfer. The transfer of genetic information can occur by at 




Transduction is the process by which a bacteriophage mediates DNA transfer from the 
donor cell to the recipient cell. Conjugation is a process whereby DNA transference is 
medicated by plasmids. Plasmids are extrachromosomal genetic elements that may 
contain resistance genes. Conjugation requires cell-to-cell contact, generally via pili to 
transfer plasmids from the donor cells to the recipient cells (McClane, et al., 1999). 
Transformation occurs when the recipient cell incorporates naked DNA that is released 
from the donor cells. DNA from a lysed donor cell can be incorporated into a recipient 
cell and integrated into its genome. The term “natural transformation” refers to the uptake 
of DNA by naturally competent cells (Chen & Dubnau, 2004). Limiting factors in the 
uptake of DNA by competent microorganisms may include: the organism’s ability to take 
up, transport, and incorporate the DNA. This condition is described by Hanssen & Sollid 
“There is a pool of virulence- and antibiotic- resistance genes in the environment in the 
form of large elements available for transfer between strains.” (Hanssen & Sollid, 2006).  
2.5.2. Gene Transfer in Staphylococci 
Penicillin resistance is more readily transferred when located on plasmids than 
when incorporated into the cellular DNA (Chambers, 2004). The methicillin resistance 
determinant on SCCmec; however, is chromosomally encoded. The transference of mecA 
harboring SCCmec is ill-defined.  In vivo interspecies transfer of mecA has been observed 
(Wielders, et al., 2001).  In this study, a methicillin-sensitive strain of S. aureus acquired 
mecA while in the presence of mecA-positive S. epidermidis and antibiotic treatment. 
Prior to antibiotic treatment, no mecA-positive S. aureus were isolated from the patient in 




isolated prior to antibiotic treatment was isogenic to the mecA-positive S. aureus isolated 
after antibiotic exposure.  This study demonstrates the possibility of mecA transference to 




 Chapter III. Methods 
3.1. Bacterial Isolates 
3.1.1. Staphylococcal strains 
Staphylococcal strains used in this study included 10 S. aureus strains previously 
isolated from mouth-guards and band musical instrument studies (Glass, et al., 2009 &  
Glass, et al., 2011) and 18 de-identified MRSA isolates from St. John’s hospital, Tulsa, 
OK. Additionally, three staphylococcal reference strains ATCC 27626, ATCC 29213, 
and ATCC 25923 (Washington D.C., ATCC) were used as controls.  
3.1.2. Characterization 
Identity of all strains was confirmed using standard procedures including, Gram 
stains, coagulase, and mannitol salt agar reactions. Ten strains of confirmed S. aureus 
were further characterized as phenotypically MRSA or MSSA by standard antibiotic 
sensitivity.  
3.1.3. Storage  
Stock cultures were maintained in Brain Heart Infusion (BHI) (Accumedia, 






Oxacillin resistance levels of bacterial strains were measured by standard macro-
broth dilution methods. This method allows for the determination of the minimum 
inhibitory concentration (MIC) of oxacillin on S. aureus isolates.  The MIC level 
indicates the lowest concentration of antibiotic that inhibits the visible growth of a 
microorganism. 
3.2.1. Media 
The broth macro-dilution method was employed using Mueller-Hinton Broth 
(MHB) (Sparks, MD, Difco) supplemented with 2% NaCl (Mallinkrodt, Paris, KY) as 
recommended by the CLSI (National Committee for Clinical Laboratory Standards) 
(Murray, et al.). 
3.2.2. Antibiotic Dilutions 
A 1 mg/ml oxacillin (St. Louis, MO, Sigma) stock solution was used. Serial 
dilutions of 128-, 64-, 32-, 16-, 8-, 4-, 2-, and 1-μg/ml oxacillin were prepared in sterile 
culture tubes containing 5 ml of MHB. Positive and negative controls were used. Neither 
the positive nor negative control contained any oxacillin. The positive control was 
inoculated with the test strain whereas the negative control was not. Additionally, for 
MSSA a lower MIC range had to be established to determine the MIC value. This was 
established by serial dilutions of 1-, 0.5-, 0.25-, 0.125-, 0.0625-, 0.03125-μg/ml oxacillin, 






A 0.5 McFarland standard was used as a reference to prepare the initial inoculums 
(Andrews, 2001). Colonies were grown overnight on Blood Agar Plates (BAP) (BBL, 
Sparks, MD) at 37C then suspended in MHB until the broth reached a 0.5 McFarland 
Standard turbidity (McFarland Standard). After serial dilution of antibiotics, each tube 
(except the negative control) was inoculated with a concentration of 5 x 10
5 
CFU/ml of 
the test strain. The tubes were incubated for aeration in an Orbit Environ-Shaker shaker 
(Lab-line Instruments Inc. Melrose Park, IL) at 37C for 24 hours. The MIC values of 
each strain were recorded as the lowest concentration in which no visible growth was 
observed. 
3.3. Genetic Analyses 
Genetic analyses of test strains indicated the presence of target genes, specifically 
the mecA gene. Only strains that qualify under the designated phenotypic and genotypic 
criteria were utilized for the transformation experiments. 
3.3.1. DNA Isolation 
DNA extraction was initially performed using the Zymo Research Bacterial 
Fungal Kit (Zymo Research, Irvine, CA). The protocol (Appendix A) was followed with 
minor modifications. Each bacterial strain was cultured in 10 ml of MHB overnight at 
37C. Cells were transferred to appropriate tubes and centrifuged at 3,000 x g for 5 
minutes. Pelleted cells were resuspended in 200 μl of UV-treated sterile water and 




Solution, the tubes were secured in the bead-beater (Mini-Beadbeater-96, BioSpec 
Products, Bartlesville, OK) and processed at maximum speed for two 3-minute sessions 
with a 1-minute resting period in between sessions. Following the bead-bashing step, 
extraction proceeded as stated in the provided ZR kit protocol. A NanoDrop 
spectrophotometer (NanoDrop Technologies, Wilmington, DE) was used to quantitate 
DNA concentration and purity of the extracted DNA (260/280 nm).  
3.3.1.1. Phenol: Chloroform DNA Extraction  
An alternative DNA extraction method, by phenol/chloroform, was employed to 
isolate intact DNA. Aliquots (1 ml) of overnight cultures were transferred into 
microcentrifuge tubes and centrifuged at 3000 x g for 5 minutes. Cells were then 
resuspended in 0.4 ml of TNE containing 2 mg/ml lysozyme and 50 U/ml lysostaphin. 
Samples were then incubated at 37C for 1 hour. Following incubation, Proteinase K 
(ProK) (400 μg/ml) and SDS (0.2%) were added to the samples and incubated at 65C for 
1 hour. Samples were extracted with an equal volume of phenol: chloroform: isoamyl 
alcohol (9:0.96:0.4) and then centrifuged at 10,000 x g for 3 minutes. The aqueous layer 
was transferred to a clean tube and extracted with an equal volume of chloroform: 
isoamyl alcohol (24:1). Samples were then centrifuged again at 10,000 x g for 3 minutes.  
The aqueous layer was transferred to another clean tube and 2 volumes of 95% ethanol 
were added to precipitate DNA. Clots of DNA were looped out and resuspended in 100 
μl of TE
-4
 buffer (10 mM Tris + 0.1 mM EDTA, pH 8.0). DNA concentration was 
measured by a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 




amplification and capillary electrophoresis were run as described in sections 3.3.2 and 
3.3.3. 
3.3.2. Polymerase Chain Reaction (PCR) 
3.3.2.1. Primers 
 Polymerase chain reactions were employed to amplify targeted gene 
sequences. Specific fluorescent labeled primers (Invitrogen, Carlsbad, CA) were 
designed for targeted gene sequences including: methicillin resistance gene mecA, 
penicillin resistance gene blaZ, coagulase gene coA, and housekeeping gene htrA. 
Sequences of the primers and PCR product sizes are listed in Table 1. 
Table 1. Primer description 
 coA primers sequence retrieved from Jones et al., 1996.  
3.3.2.2. Sample Amplification 
Previously extracted DNA was used as template DNA for the PCR. Samples were 
prepared as indicated in Table 2. All primers were ordered from Invitrogen (Carlsbad, 
















Forward 5’- GCT TCT CAA TAT GGT CCG AG -3’ FAM (blue) 132 
Reverse 5’- CTT GTT GAA TCT TGG TCT CGC -3’ 
mecA  
 




















AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA), template DNA 
(1 ng/l), and PCR water. Separate PCR were prepared for each primer pair. Forward and 
reverse primers were added to the following final concentrations in each sample: coa 
(1X) - 2 M, mecA (3X) – 3 M, htrA (2X)- 2 M, and BlaZ (1X)- 1 M.   
Table 2. PCR volumes 
  
Samples were amplified in a GeneAmp PCR System 9700 thermal cycler (Applied 
Biosystems) under the specified parameters listed in Table 3. 
Table 3. Thermal cycling parameters for PCR 
 
3.3.3. Capillary Electrophoresis 
Analyses of the PCR products were accomplished using capillary electrophoresis. 
The ABI Prism Genetic Analyzer 310 (Applied Biosystems), a single injection capillary 
Volume (µl)/ 
sample 
coA (1X), mecA (3X), 1.25 
  htrA (2X), BlaZ  (1X) 
Gold St*r Buffer  (10X) 1.25 
Taq Polymerase 0.25 
PCR Water   8.75 
Template DNA  
(1 ng/µl)   1.0 
Total Volume 12.5 
 
1 Cycle   
25 
Cycles   1 Cycle   
Initial Incubation Denature Anneal Extend Final Extension 
Final 
Step 
96°C 94°C 60°C 72°C 72°C 4°C 
11 min 30 sec 30 sec 30 sec 1 hour Hold 
 






electrophoresis system, was used to detect fluorescently tagged amplification products.  
Samples were prepared by adding 1 μl of PCR product to 25 μl of the loading solution 
containing Hi-Di formamide/ GeneScan Liz 500 size standard (100:1) (Applied 
Biosystems). Samples were run under specified parameters: run time = 20 minutes, run 
temp = 60 C, injection time = 5 seconds.  
 
3.4. Transformation 
Prior to the transformation experiments, the phenotypic and genotypic profiles of 
the potential recipient MSSA strains: HMG-5E3 (“5E3”) and HMG-5G8 and donor 
MRSA strains: SJ #3 and SJ #6 were confirmed. Macro-broth dilutions, DNA isolation, 
amplification, and capillary electrophoresis were performed as per protocols listed 
previously in sections 3.2, 3.3.1, 3.3.2.2, and 3.3.3, respectively. 
3.4.1. Feasibility Test 
The possibility of transforming MSSA strains to MRSA strains was evaluated by 
feasibility tests. Samples were prepared in sterile borosilicate test tubes (VWR, Radnoor, 
PA). Strain 5E3 was selected as the recipient MSSA test strain. Genomic DNA 
previously isolated using the Zymo Research extraction kit from SJ #3 and SJ #6 was 
used as the donor DNA. Tubes 1-4 were set up as controls to observe for any 
susceptibility changes to 5E3 with and without antibiotics (tubes 1 and 2), without MRSA 
genomic DNA (gDNA)(tube 3).  The volumes used are listed in Table 4. A 50 μl aliquot 




following times:  0 h, 2 h, 4 h, 6 h, 12 h, 24 h, 48 h. Plates were incubated at 37°C for    
24 h and observed for growth.  
Table 4. Set-up of feasibility study 




3.4.2. Nuclease Test  
A nuclease test was employed to detect potential DNA digestion by nucleases 
produced by MSSA strain 5E3. If the MRSA gDNA added is digested by nuclease 
produced by the MSSA strain, the uptake of mecA may be compromised. Therefore, 
EDTA was added to prevent DNA digestion. Oxacillin was also added to test any 
possible effects it may have on nuclease production. The final concentration of oxacillin 
added to test wells was 0.125 μg/ml (MIC1/2 of 5E3). During the initial incubation period, 
MSSA cells (5E3) were grown in MHB with and without oxacillin for two different time 
periods. The cells were incubated at 4- and 12 hours to observe any differences in 
nuclease production. Nucleases produced by the MSSA cells would remain in the 
supernatant. Therefore, the second step of the nuclease test involved exposure of the 
supernatant to MRSA gDNA.  During the exposure period, EDTA was added to prevent 











1  10 ml  ‐‐  100 μl  ‐‐ 
2  10 ml  1.25 μl  100 μl  ‐‐ 
3  10 ml  ‐‐  100 μl  15 μl 
4  10 ml  ‐‐  ‐‐  ‐‐ 






An overnight culture of 5E3 was prepared in MHB and diluted to an approximate 
concentration of 1.5 x 10
5
 CFU/ml to inoculate samples. Samples were added to a 96-
MicroWell plate. Each well contained 200 μl of MHB and the content of each sample and 
control wells are shown in Table 5. Two identical sets were prepared for each of the 
incubation periods, 4- and 12- hours. The cultures were incubated at 37ºC for the 
indicated period.  
Table 5. Nuclease set-up  
Contents of each well are listed in the table. 1-μl of 5E3 inoculum (~1.5 x 10
5
 CFU/ml)  
was added to the indicated wells. Wells 1 and 3 were to test for the effect of oxacillin on nuclease 
production. Wells 2 and 4 are controls to test for any contamination in MHB or oxacillin.   
 
3.4.2.2. Exposure to DNA 
After incubation, 200 ul of each of the sample was transferred to microcentrifuge 
tubes and centrifuged for 10 mins at 7,000 x g. The supernatant from each sample was 
transferred to another set of microcentrifuge tubes. Previously extracted MRSA gDNA 
(SJ#3 and SJ#6) were added to select tubes. EDTA was also added to observe its 
effectiveness in preventing DNA digestion. Contents of each tube are shown in Table 6. 





1  200 μl  1 μl  ‐‐ 
2  200 μl  ‐‐  ‐‐ 
3  200 μl  1 μl  2.50 μl 






Table 6. Sample exposure 
Concentration of the stock MRSA gDNA added was 24.3  g/ml.  
  Samples were incubated at 37ºC for 30 minutes.  
 
3.4.2.3. Gel electrophoresis 
After exposure to DNA, agarose electrophoresis gel (1%) was used to evaluate the 
samples from Table 6. Each sample (14 μl) was mixed with 6 μl of 1X loading dye 
(bromophenol blue) and loaded into the comb wells of the gel. A 1kb ladder (5 μl) was 
used as the standard size ladder. The gel was run for 2 hours at 75 V. 
3.4.3. Transformation 
3.4.3.1. Test Plates 
Mueller Hinton Agar (MHA) (BD, Sparks, MD) plates were prepared containing 
2 μg/ml of oxacillin. MHA control plates without oxacillin were also prepared. 
3.4.3.2. Transformation Protocols 
Three distinct sets of transformation experiments were used in this study. The two 
variables between the three sets were:  1) the DNA from the same MRSA strains was 




1  10 μl  ‐‐  10 μl of Well 1 
2  10 μl  ‐‐  10 μl of Well 2 
3  10 μl  ‐‐  10 μl of sterile water 
4  10 μl  2 μl  10 μl of Well 1 
5  10 μl  ‐‐  10 μl of Well 3 
6  10 μl  2 μl  10 μl of Well 3 
7  ‐‐  ‐‐  20 μl of Well 1 
8  ‐‐  ‐‐  20 μl of Well3 





(set A) used genomic DNA extracted via the Zymo Research DNA extraction kit with a 
one-time initial addition of oxacillin to test wells. Comparatively, the second set (set B) 
used genomic DNA extracted via the phenol/chloroform extraction method also with a 
one-time initial addition of oxacillin to test wells. The third set (set C) involved the same 
phenol/chloroform extracted DNA used in set B, however oxacillin was added at each 
sampling time point to ensure continuous antibiotic pressure. The effects of two different 
concentrations of EDTA (1 mM and 10 mM) were evaluated in each set. Because the 
oxacillin level in the culture will decrease due to uptake by the growing bacteria, a 
concentration of 0.125 μg/ml oxacillin (MIC1/2 of oxacillin for 5E3) was maintained by 
continual addition at each sample time point. An overnight 10 ml broth culture of 5E3 
was used to inoculate the test wells. Appropriate positive and negative controls were 
included. Table 7 represents the general protocol used for each set (A-C).  Detailed set-up 








Table 7. Set- up for transformation 
“+” sign denotes addition, “-“ sign denotes no addition; 5E3 inoculum was at a stock concentration of    
  1.5 x 10
5
 CFU/ml. MRSA gDNA was previously extracted from two MRSA strains: SJ #3 and SJ #6.  
3.4.3.3. Sampling 
A 10-μl aliquot was taken from each test well and dropped on both MHA control 
plates and MHA containing 2-μg/ml oxacillin plates. Sampling occurred at 7 time 
intervals: 0, 2, 4, 6, 12, 24, and 48 hours. All inoculated plates were incubated at 37°C for 
24 hours and monitored for growth. 
3.4.3.4. Colony Forming Units (CFU) 
In order to determine the number of cells initially added to each test well, serial 
dilutions of the overnight inoculum were used to determine the number of colony 
forming units (CFU). A 5-μl aliquot of the overnight inoculum (representative of the 
amount added to each test well) used to inoculate test wells was added to 100-μl of MHB 
and serially diluted (1:100). A 10-μl aliquot of each serial dilution was pipetted onto 













1  Neg ctrl 1  +  ‐  ‐  ‐  ‐  Control for 5E3 (no additions) 
2  Neg ctrl 2A  +  ‐  +  ‐  ‐  Control (antibiotic pressure, no DNA, no EDTA) 
3  Neg ctrl 2B  +  ‐  +  +  ‐  Control (antibiotic pressure, no DNA, 1mM EDTA) 
4  Neg ctrl 2C  +  ‐  +  ‐  +  Control (antibiotic pressure, no DNA, 10 mM EDTA) 
5  Neg ctrl 3A  +  +  ‐  ‐  ‐  Control (no antibiotic pressure, with DNA, no EDTA) 
6  Neg ctrl 3B  +  +  ‐  +  ‐  Control (no antibiotic pressure, with DNA, 1 mM EDTA) 
7  Neg ctrl 3C  +  +  ‐  ‐  +  Control (no antibiotic pressure, with DNA, 10 mM EDTA) 
8  Neg ctrl 4  ‐  ‐  ‐  ‐  ‐  Control for media (no additions) 
9  Test A  +  +  +  ‐  ‐  Test (MRSA gDNA and antibiotic pressure) 
10  Test B  +  +  +  +  ‐  Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) 





3.4.4. Electroporation  
Electroporation is a procedure used to introduce foreign DNA into a cell by 
increasing the permeability of the cell membrane through the application of an electrical 
pulse. This procedure was intended to be a positive control for transformation. The same 
MSSA strain, 5E3, and MRSA genomic DNA (SJ #3 and SJ #6) previously used were 
applied. Additionally, MSSA genomic DNA (extraction by Zymo kit) from 5E3 was used 
as a control.  
3.4.4.1. Sample preparation 
Fifty ml of sterile MHB was inoculated with an overnight broth culture  (1:100) of 
5E3 and incubated in a shaker at 37°C for 2-4 hours until OD550 reached 0.2- 0.9.  The 
cells were harvested by centrifugation at 3000 x g for 5 minutes. The cells were washed 
with 25 ml of ice-cold 0.5 M sucrose and centrifuged (5 minutes at 3000 x g). Cells were 
subsequently washed twice with 10 ml of 500-μl of ice-cold 0.5 M sucrose.  The final 
pellet was re-suspended in 200-250-μl of 0.5 M sucrose.   
3.4.4.2. Electroporation Procedures  
Electroporation provides a method for introducing mecA into S.aureus cells. This 
protocol for electroporation was adapted from Kohler et al., 1997. DNA (200-250ng) was 
added to 60 μl of washed cells and transferred to 1-mm gap electroporation cuvettes 
(BTX, Holliston, MA). Cells were electroporated at 1400- 1600 V.  One milliliter of 
sterile MHB was added to each cuvette and was transferred to sterile Eppendorf tubes. 
The cells were incubated in the shaker at 30°C for 2 hours.  Following incubation, 10-100 




μg/ml oxacillin.  Cultures were further screened on MHA plates containing 6 μg/ml 
oxacillin + 4% NaCl. The plates were incubated at 37°C for 24 hours and monitored for 
growth. 
3.4.4.3. Colony Polymerase Chain Reaction (PCR) 
PCR provides a fast and efficient way to screen for the presence of mecA gene 
complex after electroporation. Isolated colonies were suspended in 20-μl of sterile water 
and incubated at 95°C for 15 minutes to release DNA content. Following incubation, 




 Chapter IV. Results 
4.1. Bacterial Isolates  
In the initial characterization process, mannitol salt fermentation and coagulase 
production was monitored. A yellow zone surrounding growth on a MSA plate is 
evidence of mannitol fermentation. Coagulase production is indicated by clotting within 
the test plasma within 8 hours. Twenty-eight strains of S. aureus were tested and the 
following strains were selected for further characterization: SA 005, SJ #3, SJ #4, SJ #5, 
SJ #6, 4I2, 5E3, 9D9, 5G8, and BMI-5.Table 8 represents the results of the mannitol and 
coagulase test for the selected strains. The complete results of these tests can be found in 
Appendix C. 
Table 8 Mannitol fermentation and coagulase test results 




Fermentation Classification Source 
1 SA 005 SA 005 + + MRSA Hospital 
2 SJ #3 SJ #3 + + MRSA Hospital 
3 SJ #4 SJ #4 + + MRSA Hospital 
4 SJ #5 SJ #5 + + MRSA Hospital 
5 SJ #6 SJ #6 + + MRSA Hospital 
6 HMG 218 4I2 4I2 + + MSSA Mouth-guard 
7 HMG 207 5E3 5E3 + + MSSA Mouth-guard 
8 017 9D9 9D9 + + MSSA N/A 
9 HMG 207 5G8 5G8 + + MSSA Mouth-guard 
10 BMI-012 D5 BMI-5 + + MSSA 
Band Musical 
Instrument 
+ sign denotes strain is positive for mannitol fermentation and for coagulase and – sign, negative for 





4.2.1. Susceptibility Test 
The MIC levels of oxacillin were determined by the macro-broth dilution method. 
The results of each trial in addition to the MIC range for each strain are listed in Table 9. 
Strains that have an MIC level of greater than 4 μg/ml can be classified as MRSA and 
ones with an MIC level less than 2 μg/ml can qualify as MSSA as per the established 
interpretive criteria for MIC oxacillin by CLSI (Murray et al., 2009).  
Table 9. Minimum inhibitory concentrations of initial strain selection 
    MIC level  (µg/ml)   
Strain Trial 1 Trial 2 Trial 3 MIC range 
SA 005 64 64 32 32-64 
SJ #6 >128 128 >128 128+ 
SJ#5 64 32 32 32-64 
SJ #4 64 32 64 32-64 
SJ #3 32 64 32 32-64 
5E3 0.25 0.25 0.25 0.25 
BMI-5 0.5 0.125 0.125 0.125-0.5 
9D9 1 0.25 1 0.125-1 
5G8 1 0.25 0.25 0.25 
4I2 0.5 0.25 0.5 0.25-0.5 
*Minimum concentration range (g/ml) in which there is no visible growth  
for select MRSA and MSSA strains 
 
4.2.2. Genetic Analysis 
DNA concentration of each isolated strain was measured by NanoDrop 
spectrophotometry. The concentrations measured are indicated in Table 10. The 




transformation protocol. The additional strains, ATCC 29213 and ATCC 27626 were 
included as controls in the amplification process.  
Table 10. Concentration (ng/ μl) of  
gDNA extracted from initial selection 
 
Combined electropherograms from the genetic analyses revealed the targeted 
PCR products listed in Table 11. A positive result is registered as a peak in the expected 
PCR product size range on the electropherogram (see Figure 3 for representative 
electropherograms). Results of specific note include BMI-5 and 9D9. Referring back to 
Table 8 with the results of the coagulase and mannitol salt fermentation test, BMI-5 
tested positive for coagulase however, the gene was not detected (Table 11). 
Additionally, MIC tests indicated that 9D9 was sensitive to methicillin and therefore was 
classified as MSSA, yet mecA was detected. Otherwise, the results have been consistent 
with what was observed.  
 
  Strains Conc (ng/ml) 
1 SJ #3 42.2 
2 SJ #4 44 
3 SJ #5 41.5 
4 SJ #6 27.3 
5 SA005 44.9 
6 5E3 43.2 
7 9D9 69.4 
8 5G8 46.2 
9 4I2 27.3 
10 BMI-5 43.2 
11 ATCC 29213 9.5 
12 ATCC 27626 10.3 










 Strain BlaZ coA mecA htrA 
SA 005 + + + + 
SJ #6 + + + + 
SJ #5  + + + + 
SJ #4 + + + + 
SJ #3 + + + + 
5E3 + + - + 
BMI-5 + - - + 
9D9 + + + + 
5G8 + + - + 
4I2 + + - + 
This table is a compilation of results from electropherograms 
 “+” denotes the detection of the targeted gene product 
 “-“ denotes the absence of the targeted gene product 
Note: BMI-5: positive for phenotypic coagulase test, negative for coA 
          9D9: sensitive to oxacillin but positive for mecA 
 
  Due to the uncorrelated results, BMI-5 and 9D9 isolates were excluded from 
further tests. Additional MIC tests were performed on the remaining strains (results not 
shown). The results of the additional MIC and gene product detection tests were used in 
selecting candidates for further confirmation and for the transformation experiment. 








The MIC levels of the selected strains, MRSA isolates SJ #3 and SJ #6 and MSSA  
5E3 and 5G8,  were confirmed and are shown in Table 12. MRSA strains SJ #3 yielded a 
32 µg/ml average MIC and SJ #6 a MIC range of 32-64 µg/ml. The MIC levels for 5E3 
and 5G8 were 0.25 – 0.5 µg/ml and 0.5µg/ml, respectively. Genotypic confirmation of 
each strain was performed using PCR and subsequent analysis of PCR products on the 
Genetic Analyzer ABI 310. The results from the electropherograms are summarized in 
Table 13. 
Table 12. Confirmation of MIC values of select MRSA and MSSA 
strains 
 
After capillary electrophoresis was completed on the Genetic Analyzer ABI 310, the 
results were analyzed and visualized using the GeneMapper v3.2 software (Applied 
Biosystems). Figure 3 shows the representative electropherograms generated for SJ #3, 
SJ #6, 5G8, and 5E3. Table 13 summarizes the results compiled from the 
electropherograms for the test strains as well as the quality controls. Amplification of 
each gene (BlaZ, coA, mecA, and htrA) was run separately and the PCR products were 
combined for detection during genetic analysis. In Figure 3, the generated peaks in the 
electropherograms represent the Relative Fluorescent Units (Y-axis) versus the product 
Minimum Inhibitory Concentration (ug/ml)  
 Strain Trial 1 Trial 2 Trial 3 MIC range 
SJ #6 32 32 64 32-64 
SJ #3 32 32 32 32 
5E3 0.25 0.5 0.25 0.25-0.5 





size (X-axis) in basepairs. The fluorescence threshold was set arbitrarily at 400 RFU. 
Sample products that fluoresced at a value greater than the threshold in addition to falling 
within the product size range were registered and labeled via GeneMapper v3.2. The 
quantitative relationship between the magnitudes of fluorescence with the product 
amount is unknown.  
Figure 3. Representative Electropherograms 
* Generated peaks in electropherograms represent Relative Fluorescent Units (RFU) (Y-axis) versus the 
product size. Peaks that were higher than the set threshold (400 RFU) with the correlating product size 







Table 13. Summary of genetic analysis  
*ATCC and negative controls included for quality control 
 Because SJ #3 and SJ #6 had MIC levels greater than 4 µg/ml in addition to being 
positive for mecA, both strains were confirmed to be MRSA and were suitable for 
subsequent tests. Similarly, 5E3 and 5G8 yielded MIC levels of less than 2 µg/ml and 
were also negative for mecA, therefore were confirmed as MSSA.  
4.3.2. Feasibility Test 
The feasibility studies confirmed that cells containing the mecA gene complex 
were resistant to 2 µg/ml of oxacillin.  Cells that lacked the mecA gene complex were 
susceptible to 2 µg/ml of oxacillin. The main purpose was to test the feasibility of the 
proposed method for transformation. Revisions to the transformation test were tailored to 
the results of the feasibility test. MSSA strain 5G8 was used as the recipient strain in this 
feasibility test and MRSA strains SJ #3 and SJ 6 served as the donor strains. A mixture of 
SJ #3 and SJ #6 was used. Results of the feasibility test are summarized in Table 14. No 
growth was observed on screening MHA plates (containing 2 µg/ml oxacillin) at any of 
the 7 time points (0 – 48 hours) for any of the test samples. The negative results may 
have been attributed to the high MH broth to DNA volume ratio resulting in a final DNA 
 
Targeted Gene 
Strain BlaZ coA mecA htrA 
SJ #3 + + + + 
SJ #6 + + + + 
5E3 + + - + 
5G8 + + - + 
ATCC 25293 - - - + 
ATCC 27626 + - + - 
ATCC 29213 + + - + 





concentration of 24.3 ng/ml. Therefore, the volume of MHB was greatly reduced for 
subsequent transformation experiments.  
 
Table 14. Feasibility test results 
 
  * Sampling at 7 time points (0 – 48 hours) for all test samples yielded no   
  observable growth on test agar plates containing oxacillin.  
 
4.3.3. Nuclease Test 
Following incubation at 4- and 12- hours, samples from the nuclease test 
were loaded on a 1% agarose gel. Table 15 indicates the treatment for the sample 
placed in each lane of the gels in Figure 4. A 1-kb ladder from Axygen 
Biosciences (Union City, CA) was used. Figure 4 is the 1% agarose gel of the 
samples incubated for 4-hours. Only one gel is displayed in Figure 4 because the 
results generated from 4-hour incubation were also representative of the results 
from 12-hour incubation. Lanes 2 and 6 contain samples incubated with DNA and 
















Neg ctrl 1 + - - Control for 5G8 
No observable growth at any time 
point (0-48 hours) 
Neg ctrl 2 + - + 
Control for MRSA 
gDNA 
No observable growth at any time 
point (0-48 hours) 
Neg ctrl 3 + + - 
Control for no 
antibiotic pressure 
No observable growth at any time 
point (0-48 hours) 
Neg ctrl 4 - - - Control for MHB 
No observable growth at any time 
point (0-48 hours) 
Test + + + 
Observe transfer of 
MRSA gDNA to 
MSSA cells 
No observable growth at any time 





further migration of the digested DNA fragments (<0.3 kb) in lanes 2 and 6.  The 
DNA samples seemed to be unaffected by the addition of oxacillin. Samples 
containing EDTA (Lanes 5 and 7), however, seemed to prevent the digestion of 
DNA as migration patterns were similar to control samples containing DNA 
samples not exposed to nucleases (Lanes 3,4, and 10).  
Table 15. Samples loaded into agarose gel 
Lane Sample Treatment 
1 1 kb ladder 
2 DNA + supernatant (no oxacillin) 
3 DNA + MHB (no oxacillin) 
4 DNA + sterile water 
5 DNA + EDTA + supernatant (no oxacillin)  
6 DNA + supernatant (with oxacillin)  
7 DNA + EDTA + supernatant (with oxacillin) 
8 Supernatant (no oxacillin)  
9 Supernatant (with oxacillin) 
10 DNA + MHB (with oxacillin)  





Figure 4. Effect of nuclease production on DNA after 4-hour 
incubation 
 
*Refer to Table 15 for samples loaded into each lane of the 1% agarose gels. 
Digestion of DNA was evident (Lanes 2 and 6). However, oxacillin did not have an 
observable effect on nuclease production (Lanes 2 and 6). Samples that contained EDTA 
seemed to prevent digestion of DNA when comparing Lanes 5 and 7 (treated with EDTA) 
to the control lanes (3, 4, and 10).  
 
4.3.4. DNA integrity 
DNA (SJ #3 and SJ#6) extracted using the Zymogen DNA extraction kit was 
compared to DNA extracted using the phenol: isoamyl: chloroform extraction method. 
Figure 5 depicts two independently extracted DNA using the Zymo kit in lanes 1 and 3. 
DNA previously extracted using the phenol:isoamyl:chloroform method was loaded in 
lane 5 and a 1-kb ladder is depicted in lane 7. The Zymogen-extracted DNA in lanes 1 
and 3 showed signs of smearing whereas the phenol-extracted DNA in lane 5 showed a 




Figure 5. DNA comparison of two extraction methods 
 DNA extracted independently using the Zymogen  
  extraction kit (lane 1 and 3) compared to DNA extracted 
  using the phenol extraction method (lane 5) including New England Biolabs 1-kb ladder   
  (Ipswich, MA) (lane 7)   
   
4.3.5. Transformation Experiment 
Transformation experiments were performed on three separate occasions to 
ensure reproducibility and consistency.  In the first experiment, no visible growth was 
noted on the test plates. However, there was growth on the control plates indicating that 
transformation had not occurred. In the second experiment, no growth was observed on 
the test plates at 24-hours. The results of the second experiment were excluded due to 
contamination. The third trial yielded observable results consistent with the first trial. 
Therefore, no transformation was observed. The complete table of transformation results 





  Electroporation experiments were performed four times with appropriate controls. 
Brain Heart Infusion (BHI) media was used for the first electroporation experiment.  The 
addition of phenol-extracted MRSA genomic DNA (gDNA) to prepared MSSA cells 
resulted in colony growth on agar plates containing 2 μg/ml oxacillin. Similar results 
were observed when Zymo-extracted MRSA gDNA was added to MSSA cells.  Negative 
controls using MSSA gDNA resulted in no growth on oxacillin agar plates. Positive 
controls using oxacillin-free agar plates were consistently positive. However, the mecA 
gene was not detected by colony PCR in randomly selected colonies from any of the 
cultures. 
  In the second electroporation experiment, BHI containing 4% NaCl and 6 μg/ml 
oxacillin were used as screening plates. When phenol-extracted or Zymo-extracted 
MRSA gDNA was added to MSSA cells, confluent growth was observed on the 
screening plates and as well as on BHI plates containing only 2 μg/ml oxacillin. 
Electroporation of Zymo-extracted MSSA gDNA with MSSA cells yielded no growth on 
test plates. However, when the MSSA cells were electroporated without any DNA, lawn 
growth was also observed on test plates. There was growth on control plates.  
  An additional control was included in the third electroporation experiment. 
Prepared MSSA cells were electroporated with MRSA gDNA, MSSA gDNA, and with 
no DNA. The MSSA cells were spread on test plates without electroporation. Lawn 
growth was observed on all of the plates including the control non-antibiotic agar plates 




 The fourth electroporation experiment used different volumes of the plated cells 
(10, 20, 50, 100 μl). Isolated colonies were observed with each of the electroporation 




 Chapter V. Discussion 
The primary objective of this study was to determine the feasibility of transferring 
mecA-driven methicillin resistance to susceptible S. aureus under antibiotic pressure. The 
concept is that susceptible S. aureus could gain methicillin resistance by incorporating   
mecA-containing DNA released by MRSA.  
5.1. Strain Selection 
This study began with an initial pool of 28 clinical strains of S. aureus. Each 
strain was evaluated for the presence of mecA gene as well as for resistance to oxacillin 
by macro-broth dilutions. The selection process was to determine suitable recipients and 
donors of the mecA gene complex.   
5.1.1. Minimum Inhibitory Concentrations (MIC) 
5.1.1.1. Effect of Salt 
 MIC was used as a phenotypic indicator and allowed for the quantification 
of oxacillin resistance levels of S. aureus.  The effects of salt in the selected growth 
media were evaluated. The presence of salt resulted in higher MIC levels in MRSA 
strains, but did not have an effect on the susceptibility of MSSA strains. Thornsberry & 
McDougal found that the concentration of salt selected for MRSA in heterogenous 




5.1.2. Genetic Analysis  
5.1.2.1. Target Primers 
Four sets of primers were used in the evaluation process: BlaZ, coA, mecA, and 
htrA. BlaZ codes for resistance to penicillin G. Coagulase production (coA) is a major 
virulence factor specific for S. aureus (Johnnson, et al., 1985). The housekeeping gene, 
htrA, is also specific for S. aureus. 
5.1.2.2. Amplification 
Multiplex PCR was initially performed using three genetic markers: BlaZ, mecA, 
and htrA.  The resultant amplification products were consistent with the individual 
genotype for each strain and the controls. Attempts to amplify coA in multiplex PCR 
were unsuccessful possible due to competition among the primers of the other three 
genetic markers. Therefore, singleplex PCR for coA had to be performed for each strain 
and amplicons were then combined for detection.  
5.1.2.3. Inconsistent Profiles 
During the initial screening process, strains 9D9 and BMI-5 displayed phenotypic 
profiles inconsistent with their genotypes. MSSA strain 9D9 was sensitive to oxacillin 
even though mecA was detected. This could be due to a mutation in the mecA gene that 
prevents the expression of a functional product. Alternatively, mecA may be intact but not 
expressed in 9D9 for inexplicable reasons. Another strain, BMI-5 tested positive for 
coagulase; however, coA was not detected even after multiple attempts. coA was not 
detected possibly due to a mutation in the target sites preventing primer binding and 






5.2.1.1. Nuclease Test 
 The first attempt at transformation was negative, suggesting possible DNA 
degradation by nucleases.  In the nuclease test, ethylenediaminetetraacetic acid (EDTA) 
was used as a chelating agent to prevent nuclease action. The MSSA culture was 
incubated for 4- and 12-hours to monitor nuclease production at two different time points 
with and without the addition of oxacillin. Any nuclease present in the supernatant 
harvested would degrade the DNA added and be visualized as smearing of DNA staining 
on an agarose gel. Digestion was evident with gel electrophoresis (Figure 4). The samples 
that were not treated with EDTA (Lanes 2 and 6) were digested by nucleases as can be 
visualized on the gel in Figure 4, by the farther migration of the digested DNA fragments. 
Oxacillin did not seem to have any apparent effects on nuclease production (Lanes 2 and 
6). Furthermore, EDTA seemed to prevent the digestion of DNA in the presence of 
nucleases. Smearing of DNA samples observed in the gel suggested possible shearing of 
extracted DNA.  
5.2.1.2. DNA Extraction 
 DNA was extracted using the Zymo Research kit and the 
phenol/chloroform method. The extraction products were loaded on an agarose gel. A 
slurring pattern was visualized with Zymo-extracted DNA as compared to the distinct 
bands manifested by the phenol/chloroform-extracted DNA (Figure 5). The Zymo-




was believed to be due to the mechanical stress placed on the DNA during this extraction 
process. Therefore, donor MRSA gDNA was extracted by the phenol method. 
5.2.2. Transformation 
Three transformation experiments were performed with no observed 
transformation. During the second trial, randomly distributed growth was observed only 
after 48 h of incubation. Transformation did not occur at 48-hours because the growth 
was randomly distributed, even on control plates. Also, mecA was not detected from the 
growth. The growth observed was possibly due to the exhaustion of oxacillin in the agar 
plates by 48 hours therefore permitting growth. The results of the transformation 
experiment suggest that the conditions or circumstances may not have been favorable for 
transference to occur. Even under continual antibiotic pressure, transformation was not 
observed. In vitro attempts at interspecies transfer of SCCmec have been unsuccessful in 
the past (Bloemendaal et al., 2010).  
5.2.3. Electroporation 
 Electroporation is a procedure used to introduce foreign DNA into the cell 
by increasing the permeability of the cell membrane with the application of an electrical 
pulse. This procedure was intended to be a positive control to show that 5E3 has the 
ability to integrate MRSA gDNA. Transformation of MSSA to MRSA using 
electroporation was not successful after four attempts. Likewise, the mecA gene was not 




5.2.4. Interpretation of Results 
 Although in vivo interspecies transfers may have occurred (Bloemendaal 
et al. 2010), transformation may not be associated with mecA transfer. Alternatively, 
conjugation or transduction may be the mechanisms responsible for the observed transfer 
of methicillin resistance. Ito et al. (1999) found that SCC mecA cassette lacks the genes 
for conjugation and transduction. Whether or not these criteria are applicable to all 
SCCmec are unknown. The reason this transformation did not take place may be due to 
the unique nature of the MRSA gDNA or the MSSA strain, 5E3. With 5 known types of 
SCCmec, ranging in size from 21- to 67-kb, the size of the element may be a factor in 
transformation with the larger element being more difficult to transfer. Types I, II, and III 
are most commonly associated with HA-MRSA; whereas Types IV and V are generally 
found in CA-MRSA. Types IV and V, being significantly smaller in size than the other 
types (21 kb and 28 kb, respectively), may be more readily incorporated into the bacterial 
cell genome. (Ito et al., 2004) An indication of the SCCmec type in the gDNA extract 
used in this study could have provided some insight into transference. Alternatively, 
transformation may have been unsuccessful due to the inability of MSSA 5E3 to 
incorporate mecA into its genome. Integration of SCCmec is site-specific on the 
staphylococcal chromosome. The locus for integration is known as the SCCmec 
attachment site (attB). The study of this locus may be important in understanding how 
receptive a MSSA isolate is to mecA. Differences in attB sequence of MSSA isolates 
have suggested the possibility that some MSSA strains may lack the ability to integrate 
SCCmec elements into their chromosomes (Noto et al., 2008). Although EDTA 




compromised transformation by preventing the uptake or integration of DNA (Noteborn, 
et al., 1981). The direct effect of EDTA on SCCmec and transformation of S. aureus may 
have to be further explored.  
5.3. Future Studies 
The results of this study indicate that the transference of methicillin resistance 
between sensitive and resistant strains is a poorly understood process. This study 
addressed one of the three possible mechanisms by which methicillin-resistance can be 
transferred, transformation. The inability to accomplish transformation indicates that this 
process is most likely not the in vitro mechanism whereby methicillin resistance is 
transferred among clinical isolates of Staphylococcus. Future studies will address the 
transference of resistance using either transduction and/or conjugation. Additionally, 
further analysis of the SCCmec and its site specific integration into the genome may be 
necessary to understand the potential or capacity for transference. Furthermore, using 
combinations of other S. aureus strains or staphylococcal species (e.g. Staphylococcus 








      Appendix  
Appendix A   
ZR Fungal/Bacterial DNA Kit  D6005 (modified) 
Protocol:  
1. Add 50-100 mg fungal or bacterial cells that have been resuspended in up to 
200 ul of water or isotonic buffer (e.g.  PBS) or up to 200 mg of tissue to a ZR 
BashingBead Lysis Tube. Add 750 ul Lysis Solution to the tube. 
** Transferred from glass tubes to 15 ml purple top tube and centrifuged 
for about 3,000 x g , 5 mins. Discard supernatant and resuspend pellet in 
200 ul of water, and added to BashingBead Lysis Tube ** 
**Transfer (100 ul /sample) DNA elution buffer to microcentrifuge tubes 
and place in 60°C water bath** 
2. Secure in a Biospec bead beater (Bartlesville, OK), fitted with a 2 ml tube 
holder assembly and process at maximum speed for 5 minutes 
** Balance, secure, set for 3 minutes, turn “on”,  press “press to start” 
(yellow button), let rest for 1 minute, press yellow button again** 
3. Centrifuge the ZR BashingBead Lysis Tube in a microcentrifuge at ≥10,000 
x g for 1 minute. 
4. Transfer up to 400 ul supernatant to a Zymo-Spin IV Spin Filter (orange 
top) in a Collection Tube and centrifuge at 7,000 rpm (~7,000 x g) for 1 
minute.  
5. Add 1,200 ul of Fungal/ Bacterial DNA Binding Buffer to the filtrate in the 
Collection Tube  from Step 4.  
6. Transfer 800 ul of the mixture from Step 5 to a Zymo-Spin IIC Column in a 
Collection Tube and centrifuge  at 10,000 x g for 1 minute. 
7. Discard the flow through from the Collection Tube and repeat Step 6. 
8. Add 200 ul DNA Pre-Wash Buffer to the Zymo-Spin IIC Column in a new 
Collection Tube and centrifuge at 10,000 x g for 1 minute.  
9. Add 500 ul Fungal/Bacterial DNA Wash Buffer to the Zymo-Spin IIC 
Column and centrifuge at 10,000 x g for 1 minute. 
10. Transfer the Zymo-Spin IIC Column to a clean 1.5 ml microcentrifuge tube 
and add 100 ul DNA Elution Buffer directly to the column matrix. **Let sit 
for at least 10 minutes** Centrifuge at 10,000 x g for 30 seconds to elute the 
DNA.  
** Set in water bath 60°C waterbath** 







Transformation trial set-up 
Set A: Use *MRSA gDNA from Zymo kit extraction (sheared DNA) 
  
 
Strain 5E3 (MSSA, MIC 0.25 ug/ml) 
     
 















1 Neg ctrl 1 195.0 5 - - - - - ctrl for transference, + ctrl for growth MRSA gDNA = 24.3 ng/ul 
 
2 Neg ctrl 2A 192.5 5 - 2.5 - - - ctrl (antibiotic pressure, no DNA) 
  
 
3 Neg ctrl 2B 190.5 5 - 2.5 2 - - ctrl (antibiotic pressure, no DNA, 1mM EDTA) oxacillin = 0.01 mg/ml 
 
4 Neg ctrl 2C 191.3 5 - 2.5 - 1.2 - ctrl (antibiotic pressure, no DNA, 10 mM EDTA) 
  
 
5 Neg ctrl 3A 179.0 5 16 - - - - ctrl (no antibiotic pressure, with DNA) EDTA (1 mM)= 100 mM 
 
6 Neg ctrl 3B 177.0 5 16 - 2 - 




7 Neg ctrl 3C 177.8 5 16 - - 1.2 
- ctrl (no antibiotic pressure, with DNA, 10 mM 
EDTA EDTA(10 mM) = 250 mM 
 
8 Neg ctrl 4 200.0 - - - - - - ctrl for growth in media 
  
 
9 Test A 176.5 5 16 2.5 - - Test with MRSA gDNA and antibiotic pressure 
  
 
10 Test B 174.5 5 16 2.5 2 - 




11 Test C 175.3 5 16 2.5 - 1.2 




All volumes added were in microliters (ul). An overnight culture of MSSA strain 5E3 was used to inoculate. 






Transformation trial set-up (continued) 
Set B: Use *MRSA gDNA (SJ #3 and SJ #6) from phenol extraction 
  
 
Strain 5E3 (MSSA, MIC 0.25 ug/ml) 
     
 
















1 Neg ctrl 1 195.0 5 - - - - - ctrl for transference, + ctrl for growth 
MRSA gDNA = 70 
ng/ul 
 
2 Neg ctrl 2A 192.5 5 - 2.5 - - - ctrl (antibiotic pressure, no DNA) 
  
 
3 Neg ctrl 2B 190.5 5 - 2.5 2 - 
- ctrl (antibiotic pressure, no DNA, 1mM 
EDTA) oxacillin = 0.01 mg/ml 
 
4 Neg ctrl 2C 191.3 5 - 2.5 - 1.2 




5 Neg ctrl 3A 189.0 5 6 - - - - ctrl (no antibiotic pressure, with DNA) 
EDTA (1 mM)= 100 
mM 
 
6 Neg ctrl 3B 187.0 5 6 - 2 - 




7 Neg ctrl 3C 187.8 5 6 - - 1.2 
- ctrl (no antibiotic pressure, with DNA, 10 mM 
EDTA 
EDTA (10 mM) = 250 
mM 
 
8 Neg ctrl 4 200.0 - - - - - - ctrl for growth in media 
  
 
9 Test A 186.5 5 6 2.5 - - Test with MRSA gDNA and antibiotic pressure 
  
 
10 Test B 184.5 5 6 2.5 2 - 




11 Test C 185.3 5 6 2.5 - 1.2 













Appendix  B 
 
 
Transformation set-up (continued) 
Set C: Used *MRSA gDNA (SJ #3 and SJ #6) from phenol extraction - Continuous antibiotic pressure 
 
 
Strain:  5E3 (MSSA, MIC 0.25 ug/ml) 
    
 









EDTA        
(10 
mM) Comments Stock solutions 
 
1 Neg ctrl 1 195.0 5 - - - - - ctrl for transference, + ctrl for growth 
MRSA gDNA = 70 
ng/ul 
 
2 Neg ctrl 2A 192.5 5 - 2.5 - - - ctrl (antibiotic pressure, no DNA) 
 
 
3 Neg ctrl 2B 190.5 5 - 2.5 2 - 
- ctrl (antibiotic pressure, no DNA, 1mM 
EDTA) oxacillin = 0.01 mg/ml 
 
4 Neg ctrl 2C 191.3 5 - 2.5 - 1.2 




5 Neg ctrl 3A 189.0 5 6 - - - - ctrl (no antibiotic pressure, with DNA) 
EDTA (1 mM)= 100 
mM 
 
6 Neg ctrl 3B 187.0 5 6 - 2 - 




7 Neg ctrl 3C 187.8 5 6 - - 1.2 
- ctrl (no antibiotic pressure, with DNA, 10 
mM EDTA 
EDTA (10 mM) = 250 
mM 
 
8 Neg ctrl 4 200.0 - - - - - - ctrl for growth in media 
 
 
9 Test A 186.5 5 6 2.5 - - 




10 Test B 184.5 5 6 2.5 2 - 




11 Test C 185.3 5 6 2.5 - 1.2 
Test with MRSA gDNA, antibiotic pressure, 
10 mM EDTA 
 
 







Initial Characterization of S. aureus strains   





Fermentation Classification Source 
1 SA 001 SA 001 + + MRSA Hospital 
2 SA 002 SA 002 + + MRSA Hospital 
3 SA 003 SA 003 + + MRSA Hospital 
4 SA 004 SA 004 + + MRSA Hospital 
5 SA 005* SA 005 + + MRSA Hospital 
6 SA 006 SA 006 - - MRSA Hospital 
7 SA 007 SA 007 + + MRSA Hospital 
8 SA 008 SA 008 + + MRSA Hospital 
9 SA 009 SA 009 + + MRSA Hospital 
10 SA 010 SA 010 + + MRSA Hospital 
11 SA 011 SA 011 + + MRSA Hospital 
12 SJ #1 SJ #1 + - MRSA Hospital 
13 SJ #2 SJ #2 + + MRSA Hospital 
14 SJ #3* SJ #3 + + MRSA Hospital 
15 SJ #4* SJ #4 + + MRSA Hospital 
16 SJ #5* SJ #5 + + MRSA Hospital 
17 SJ #6* SJ #6 + + MRSA Hospital 
18 SJ #7 SJ #7 + + MRSA Hospital 
19 HMG 218 4I2 4I2 + + MSSA Mouthguard 
20 HMG 207 5E3 5E3 + + MSSA Mouthguard 
21 HMG 218 4I3 4I3 - - MSSA Mouthguard 
22 FMP 143-46 2A9 2A9 - - MSSA Mouthguard 
23 HMG 213 4I1 4I1 - + MSSA Mouthguard 
24 014 10H1 10H1 - - MSSA N/A 
25 017 9D9 9D9 + + MSSA N/A 
26 HMG 207 5G8 5G8 + + MSSA Mouthguard 




28 HMG 206 6A7 6A7 - + MSSA Mouthguard 
“+”- sign denotes a positive result for mannitol fermentation or coagulase 





Complete Transformation (Trials 1-3) Results 
Transformation results: Trial 1 
 
No representative photos available for trial 1 



















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
11 Test (MRSA gDNA, antibiotic pressure, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
(+) indicates growth, (‐) indicates no growth Oxa MHA‐ Mueller Hinton Agar plates contained 2 ug/ml oxacillin
















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
11 Test (MRSA gDNA, antibiotic pressure, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
(+) indicates growth, (‐) indicates no growth Oxa MHA‐ Mueller Hinton Agar plates contained 2 ug/ml oxacillin
Set C: Used MRSA gDNA from phenol extraction‐ Continual antibiotic pressure



















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +





Appendix D continued 
Transformation results: Trial 2  
 
Representative plates on the right of each photo is an MHA plate without oxacillin, plate on the left of each photo is an MHA plate containing 2 
µg/ml of oxacillin. 
 



















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +






Appendix D continued 
 
Transformation results: Trial 2  
 
 
Representative plates on the right of each photo is an MHA plate without oxacillin, plate on the left of each photo is an MHA plate containing 2 
µg/ml of oxacillin. 
Set B: Used *MRSA gDNA from phenol extraction



















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +






Appendix D continued 
 
Transformation results: Trial 2 (continued)  
  
Representative plates on the right of each photo is an MHA plate without oxacillin, plate on the left of each photo is an MHA plate containing 2 
µg/ml of oxacillin. 
Set C: Used MRSA gDNA from phenol extraction‐ Continual antibiotic pressure



















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + + +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
11 Test (MRSA gDNA, antibiotic pressure, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
(+) indicates growth, (‐) indicates no growth Oxa MHA‐ Mueller Hinton Agar plates contained 2 ug/ml oxacillin





Appendix D continued 
 
Transformation results: Trial 3 
 
Representative plates on the right of each photo is an MHA plate without oxacillin, plate on the left of each photo is an MHA plate containing 2 
µg/ml of oxacillin. 



















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +






Appendix D Continued 
Transformation results: Trial 3 (continued) 
 
Representative plates on the right of each photo is an MHA plate without oxacillin, plate on the left of each photo is an MHA plate containing 2 
µg/ml of oxacillin. 



















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +





Appendix D Continued 
Transformation results: Trial 3 (continued) 
 
Representative plates on the right of each photo is an MHA plate without oxacillin, plate on the left of each photo is an MHA plate containing 2 
µg/ml of oxacillin
Set C: Used MRSA gDNA from phenol extraction‐ Continual antibiotic pressure



















1 Control for 5E3 (no additions) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
2 Control (antibiotic pressure, no DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
3 Control (antibiotic pressure, no DNA, 1mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
4 Control (antibiotic pressure, no DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
5 Control (no antibiotic pressure, with DNA, no EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
6 Control (no antibiotic pressure, with DNA, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
7 Control (no antibiotic pressure, with DNA, 10 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
8 Control for media (no additions) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 Test (MRSA gDNA and antibiotic pressure) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
10 Test (MRSA gDNA, antibiotic pressure, 1 mM EDTA) ‐ + ‐ + ‐ + ‐ + ‐ + ‐ + ‐ +
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Scope and Method of Study: The specific aim of this study was to document the transfer 
of a functional methicillin resistance gene, mecA, from methicillin resistant 
Staphylococcus aureus (MRSA) genomic DNA to methicillin sensitive 
Staphylococcal aureus (MSSA) thereby converting MSSA to MRSA. The 
experimental approach included the characterization of Staphylococcus aureus 
strains using Gram stain, coagulase and mannitol salt agar tests. Included among 
the Staphylococcus strains analyzed were 18 de-identified MRSA hospital 
isolates, nine MSSA strains isolated from band musical instruments and mouth-
guards studies, and one MSSA strain of unknown origin. Additionally, sensitivity 
profiles of each strain were determined by minimum inhibitory concentration 
(MIC). Detection of mecA gene involved amplification by polymerase chain 
reaction (PCR) using fluorescently tagged primers and capillary electrophoresis 
with an ABI Prism Genetic Analyzer 310. Transformation studies involved the 
suspension of DNA extracted from two MRSA strains into a MSSA culture 
containing oxacillin complete with necessary controls. Electroporation was used 
in an attempt to force transformation, but it too was unsuccessful. 
 
Findings and Conclusions: Transformation was not observed under the specific test 
conditions. As a result of the electroporation experiment, growth was observed 
but no mecA gene was detected. The difficulty in transforming MSSA to MRSA 
suggests that transformation of SCCmec containing a mecA gene may not readily 
occur in nature or if so, it may proceed under conditions that were not replicated 
in vitro. Furthermore, additional analysis of SCCmec containing a mecA gene of 
the Staphylococcal strains may be necessary to further assess the integration of 
mecA into a recipient’s genome. Lastly, transference of mecA to MSSA may be a 
result of conjugation or transduction, not transformation.  
 
